BI 1950

BI 1950 : Inhibitor of ITGAL

Structure

Information

  • ITGAL
  • Inhibitor
  • 100 nM

In Vitro Validations

Uniprot ID: P20701
Target Class: Integrin
Target SubClass: --
Potency: Kd
Potency Value: 9 nM
Potency Assay: ITGAL binding assay
PDB ID for probe-target interaction (3D structure): --
Target aliases:
Integrin alpha-L, CD11A, ITGAL, ITAL_HUMAN, LFA-1A ...

DOI Reference: 10.1002/jlcr.3698

In Cell Validations

In Vivo Data

Off-Target Selectivity Assesments

Probe Selectivity in Vitro:
Selectivity within target family: Selective (>1000 fold) against closely related ITGB2 and ITGB1. Selectivity outside target family: Cerep Panel at 10 µM; BI-1950 hit 4/47 off targets > 50 %, all four (CA+/DHPSI/RA, CA+/PAASITE, NA+/SITE2/RA and THRO SYN(HU)) : IC50 > 3 µM; Clean GPCR scan
I have extra information to add

SERP ratings and comments


SERP Ratings

In Cell Rating
In Model Organisms

SERP Comments:

Lymphocyte function-associated antigen 1 (LFA-1) is is a heterodimeric glycoprotein with non-covalently linked subunits ITGAL (CD11a) and ITGB2 (CD18), that is expressed in all leukocytes and involved in cellular adhesion and costimulatory signaling. BI-1950 binds selectively to the I domain of ITGAL thus inhibiting the interaction between LFA-1 and its major ligand ICAM-1 (intercellular adhesion molecule 1) with high specificity and good potency. The close analog BI-9446 can be used as negative control for in vitro studies as it shows weaker affinity to ITGAL (> 1µM). A co-crystal structure of close analogue compound 17d with ITGAL

(last updated: 3 Mar 2022 )

SERP Ratings

In Cell Rating
In Model Organisms

SERP Comments:

BI-1950 has both strong binding affinity to the target protein LFA1 and potent activity in IL-2 cellular assays using both PBMCs and whole blood. The plasma protein binding is high, so this should be considered when serum/albumin is present in assay media. There is a strong data pack around selectivity which indicates that no concerning off-target activity has been identified. When considering the use of BI-1950 in rodent efficacy models it is important to take into consideration 250-fold weaker activity in IL-2 assays using mouse splenocytes compared with human PBMCs. Although the PK parameters have been disclosed, I do not believe that total or free drug levels have been shared which would be useful.

(last updated: 11 Mar 2022 )